[This retracts the article DOI: 10.1155/2022/4817488.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791425 | PMC |
| http://dx.doi.org/10.1155/2024/9859863 | DOI Listing |
Publication Analysis
Top Keywords
retracted zonisamide's
4
zonisamide's efficacy
4
efficacy safety
4
safety parkinson's
4
parkinson's disease
4
disease dementia
4
dementia lewy
4
lewy bodies
4
bodies meta-analysis
4
meta-analysis systematic
4
Similar Publications
Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
Biomed Res Int
September 2022
The First Clinical Medical College, Shandong University of Chinese Medicine, Jinan, China.
Objective: Clinical data has recently shown an association between Parkinson's disease (PD), Dementia with Lewy bodies (DLB), and zonisamide. The purpose of this study was to thoroughly evaluate the efficacy and safety of zonisamide in PD and DLB.
Methods: Pubmed, the Cochrane Library, Web of Science, and Embase databases were searched for all randomized clinical trials (RCTS) on the role of zonisamide in PD and DLB that were completed by April 18, 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!